Bayer, Versant join forces on $225M Series A for stem cell upstart – FierceBiotech
FierceBiotech |
Bayer, Versant join forces on $225M Series A for stem cell upstart
FierceBiotech The startup, which is being hailed by the pair as a “next-generation regenerative medicine company” plans to develop best-in-class induced pluripotent stem cell (iPSC) therapies. Its initial focus will be on CNS and CV disease areas, the companies said … Bayer and Versant Ventures Join Forces to Launch Stem Cell Therapy Company BlueRock Therapeutics with USD 225 …PR Newswire (press release) Bayer launches stem cell therapy company BlueRock TherapeuticsSeeking Alpha Bayer, Versant invest $225 million in biotech ventureReuters Channel NewsAsia all 4 news articles » |
The Daily Nonpareil |
Miller ‘cautiously optimistic’ after Council Bluffs stem cell transplant to treat myeloma
The Daily Nonpareil “The doctors here thought I was too old for a stem cell transplant,” Miller said. “Although I was 75, I had kept myself in pretty good shape, and the specialist I saw at the Mayo Clinic was confident that, despite my age, I could tolerate the stem cell … Stem Cell Therapy for Anti-Aging: Does It Work?Diets In Review (blog) |